2023 World Conference on Lung Cancer (Posters)-P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial

P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial - PDF(Abstract)

Back to course

Pdf Summary

A phase 2 trial investigated the efficacy and safety of camrelizumab, an anti-programmed cell death-1 antibody, combined with apatinib, a small-molecule tyrosine kinase inhibitor, as first-line treatment for advanced squamous non-small-cell lung cancer (NSCLC). The study found that the combination treatment showed promising antitumor activity in patients with advanced squamous NSCLC, with a manageable safety profile. <br /><br />A total of 32 patients were enrolled in the trial and received camrelizumab and apatinib until disease progression or intolerable toxicity. The median progression-free survival (PFS) was 8.3 months, and the objective response rate (ORR) was 78.1%. The median overall survival (OS) was 21.7 months. The efficacy of the treatment was similar across different subgroups based on disease stage, programmed cell death-ligand 1 (PD-L1) expression, and tumor mutation burden (TMB). <br /><br />The most common treatment-emergent adverse events (TEAEs) were proteinuria, hypertension, increased alanine aminotransferase, increased aspartate aminotransferase, rash, and palmar-plantar erythrodysesthesia syndrome. Grade 3-4 TEAEs included proteinuria, increased aspartate aminotransferase, increased alanine aminotransferase, decreased platelet count, and interstitial pneumonia. There were no grade 3 hemorrhage events reported. <br /><br />Overall, the study suggests that the combination of camrelizumab and apatinib as a first-line chemo-free treatment is effective and well-tolerated in patients with advanced squamous NSCLC. The results provide evidence for the use of immunotherapy combined with antiangiogenic agents in the treatment of advanced NSCLC.

Asset Subtitle

Jinliang Wang

Meta Tag

Speaker Jinliang Wang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

phase 2 trial

efficacy

safety

camrelizumab

apatinib

squamous NSCLC

progression-free survival

objective response rate

overall survival

immunotherapy